obecabtagene autoleucel
Autolus Reports Steady Progress for Aucatzyl's US Launch, Anticipating European Approvals in 2025
The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.
FDA Approves Autolus' CAR T-Cell Therapy Aucatzyl for B-Cell Acute Lymphoblastic Leukemia
The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.